Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: A 13-week, randomized, double-blind comparison with celecoxib and placebo

Clinical Therapeutics

Volumn 27, Issue 1, 2005, Pages 64-77

  Sheldon, Eric ^a   Beaulieu, André ^b   Paster, Zorba ^c   Dutta, Dipen ^d   Yu, Sue ^d   Sloan, Victor S ^d  

^a MIAMI RESEARCH ASSOCIATES   (United States)

^b UNIVERSITÉ LAVAL   (Canada)

^c DEAN MEDICAL CENTER   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Celecoxib; Cyclooxygenase 2 selective inhibitors; Knee; Lumiracoxib; Osteoarthritis

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; ANTICOAGULANT AGENT; CELECOXIB; CHONDROITIN SULFATE; CORTICOSTEROID; DIACETYLRHEIN; GLUCOSAMINE SULFATE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYALURONIC ACID; LUMIRACOXIB; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HEADACHE; HEART INFARCTION; HUMAN; INFLUENZA; KNEE; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VISUAL ANALOG SCALE;

EID: 14844336962     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.01.002     Document Type: Article

References (38)

1. Woolf A.D., and Pfleger B. Burden of major musculoskeleta conditions Bull World Health Organ 81 2003 646 656
2. Dominick K.L., Ahern F.M., Gold C.H., and Heller D.A. Health-related quality of life among older adults with arthritis Health Qual Life Outcomes 2 2004 5
3. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 Update Arthritis Rheum 43 2000 1905 1915
4. Jordan K.M., Arden N.K., and Doherty M. Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT) EULAR recommendations 2003: An evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committeefor International Clinical Studies Including Therapeutic Trials (ESCISIT) Ann Rheum Dis 62 2003 1145 1155
5. Schnitzer T.J., and American College of Rheumatology Update of ACR guidelines for osteoarthritis: Role of the coxibs J Pain Symptom Manage 23 Suppl 4 2002 S24 S34
6. Dougados M. The role of anti-inflammatory drugs in the treatment of osteoarthritis: A European viewpoint Clin Exp Rheumatol 19 Suppl 25 2001 S9 S14
7. Moskowitz R.W. The role of anti-inflammatory drugs in the treatment of osteoarthritis: A United States viewpoint Clin Exp Rheumatol 19 Suppl 25 2001 S3 S8
8. Hernandez-Diaz S., and Garcia Rodriguez L.A. Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs Am J Med 110 Suppl 3A 2001 20S 27S
9. [published correction appears in N Engl J Med. 1999;341:548] Wolfe M.M., Lichtenstein D.R., and Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs N Engl J Med 340 1999 1888 1899
10. Moore R.A. The hidden costs of arthritis treatment and the cost of new therapy--the burden of non-steroidal antiinflammatory drug gastropathy Rheumatology (Oxford) 41 Suppl 1 2002 7 15
11. McKenna F., Borenstein D., and Wendt H. Celecoxib versus diclofenac in the management of osteoarthritis of the knee Scand J Rheumatol 30 2001 11 18
12. Deeks J.J., Smith L.A., and Bradley M.D. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: Systematic review of randomised controlled trials BMJ 325 2002 619 627
13. Kivitz A.J., Greenwald M.W., and Cohen S.B. Protocol 085 Study Investigators Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: A randomized controlled trial J Am Geriatr Soc 52 2004 666 674
14. Bombardier C., Laine L., Reicin A. VIGOR Study Group Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis N Engl J Med 343 2000 1520 1528
15. Warner T.D., and Mitchell J.A. Cyclooxygenases: New forms, new inhibitors, and lessons from the clinic FASEB J 18 2004 790 804
16. Abstract FRI0300 Scott G., Rordorf C., and Blood P. Dose escalation study to assess the safety, tolerability, pharmaco kinetics and pharmacodynamics of COX189 in healthy subjects Ann Rheum Dis 61 Suppl 1 2002 242
17. Abstract P-199 Hartmann S., Scott G., and Rordorf C. Lumiracoxib demonstrates high absolute bioavailability in healthy subjects Tulunay F.C. Orme M. European Collaboration: Towards Drug Development and Rational Drug Therapy. Proceedings o f the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics 2003 Springer-Verlag Berlin
18. Abstract FRI0235 Scott G., Branson J., and Milosavljev S. Lumiracoxib demonstrates close-proportional and time-independent pharmacokinetics in patients with osteoarthritis of the knee Ann Rheum Dis 62 Suppl 1 2003 267
19. Mangold J.B., Gu H., and Rodriguez L.C. Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects Drug Metab Dispos 32 2004 566 571
20. Scott G., Rordorf C., and Reynolds C. Pharmacokinetics of lumiracoxib in plasma and synovial fluid Clin Pharmacokinet 43 2004 467 478
21. Abstract AB0042 Dawson J., Jagher B., and Toscano K.T. Lumiracoxib shows rapid distribution to inflamed sites in a rat tissue chamber model compared with rofecoxib and celecoxib Ann Rheum Dis 62 Suppl 1 2003 377
22. Abstract AB0044 Weaver M.L., Flood D.J., Kimble F.F., and Fujimoto R.A. Lumiracoxib demonstrates preferential distribution to inflamed tissue in the rat-following a single oral dose: An effect not seen with other cyclooxygenase-2 inhibitors Ann Rheum Dis 62 Suppl 1 2003 378
23. Day R.O. Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: A rheumatologist's perspective Clin Exp Rheumatol 19 Suppl 25 2001 559 562
24. Schnitzer T.J., Burmester G.R., Mysler E. TARGET Study Group Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction inulcer complications: Randomised controlled trial Lancet 364 2004 665 674
25. Abstract FRI0233 Fleischmann R., Sheldon E., and MaldonadoCocco J. A prospective randomised 13-week study evaluating the efficacy of lumiracoxib in patients with osteoarthritis of the knee Ann Rheum Dis 62 Suppl 1 2003 266
26. Tannenbaum H., Berenbaum F., and Reginster J.Y. Lumiracoxib is effective in the treatment of osteo arthritis of the knee: A 13 week, randomised, double blind study versus placebo and celecoxib Ann Rheum Dis 63 2004 1419 1426
27. Abstract FRI0246 Benevolenskaya L., Tüzün S., and Hagin E. Lumiracoxib is effective in relieving symptoms of knee or hip osteoarth ritis after 4 weeks of treatment: Results from a randomized, placebo-controlled trial Ann Rheum Dis 62 Suppl 1 2003 270
28. Altman R., Asch E., and Bloch D. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee Arthritis Rheum 29 1986 1039 1049
29. Bellamy N., Buchanan W.W., and Goldsmith C.H. Validation study of WOMAC: A health status instru ment for measuring clinically important patient relevant outcomes to antirheumatic drug therapyin patients with osteoarthritis of the hip or knee J Rheumatol 15 1988 1833 1840
30. Dougados M., Leclaire P., and van der Heijde D. Response criteria for clinical trials on osteoarthritis of the knee and hip: A report of the Osteoarthritis Research Society International StandingCommittee for Clinical Trials Response Criteria Initiative Osteoarthritis Cartilage 8 2000 395 403
31. Pham T., van der Heijde D., and Lassere M. OMERACT OARSI Outcome variables for osteoarthritis clini cal trials: The OMERACT-OARSI set of responder criteria J Rheumatol 30 2003 1648 1654
32. Tubach F., Ravaud P., and Baron G. Evaluation of clinically relevant changes in patient-reported out comes in knee and hip osteoarthritis: The minimal clinically important improvement Ann Rheum Dis 64 2005 29 33
33. [published correction appears in Drugs. 2001; 61:498] Clemett D., and Goa K.L. Celecoxib: A review of its use in osteoarthritis, rheumatoid arthritis and acute pain Drugs 59 2000 957 980
34. Hawkey C.C., Svoboda P., and Fiedorowicz-Fabrycy I.F. Gastroduodenal safety and tolerability of lumiracoxib compared with ibuprofen and celecoxib in patients with osteoarthritis J Rheumatol 31 2004 1804 1810
35. Abstract 87 Hawkey C., Hoexter G., and Richard D. Lumiracoxib, a novel cyclooxygenase-2 selective inhibitor, has improved gastrointestinal safety and tolerability compared with nonselectivenonsteroidal anti-inflammatory drugs: A pooled analysis Arthritis Rheum 48 Suppl 9 2003 79
36. Fitzgerald G.A. Coxibs and cardiovascular disease N Engl J Med 351 2004 1709 1711
37. [published correction appears in BMJ. 1994;308: 1540] Antiplatelet Trialists' Collaboration Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ 308 1994 81 106
38. Farkouh M.E., Kirshner H., Harrington R.A. TARGET Study Group Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET,cardiovascular outcomes: Randomised controlled trial Lancet 364 2004 675 684